Baird Downgrades Longboard Pharmaceuticals Inc (LBPH) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq edge higher ahead of midterm results; Apple falls
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts LBPH Hot Sheet
Price: $59.98 --0%
Rating Summary:
3 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 12
Rating Summary:
3 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 12
Join SI Premium – FREE
Baird analyst Joel Beatty downgraded Longboard Pharmaceuticals Inc (NASDAQ: LBPH) from Outperform to Neutral with a price target of $60.00.
For an analyst ratings summary and ratings history on Longboard Pharmaceuticals Inc click here. For more ratings news on Longboard Pharmaceuticals Inc click here.
Shares of Longboard Pharmaceuticals Inc closed at $38.90 yesterday.
You May Also Be Interested In
- Rosenblatt cuts Roku to Neutral as Fox merger nears closing
- JPMorgan Downgrades Bank of Shanghai (601229:CH) to Underweight
- Goldman Sachs Downgrades China Southern Airlines Co Ltd. (600029:CH) to Sell
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
